<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        48-249-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MONTAPINE 10 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEMANTINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06DX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The brain contains N-methyl-D-aspartate (NMDA) receptors that are involved in transmitting nerve signals and may be important for learning and memory. Abnormal transmission of nerve signals through NMDA-receptors in the brain may affect memory and other mental functions and contribute to symptoms of Alzheimer&rsquo;s disease. MONTAPINE belongs to a group of medicines called NMDA-receptor antagonists. The action of MONTAPINE on NMDA receptors may help normalize the transmission of nerve signals, which may help slow the decline in some of the symptoms of Alzheimer disease.</p><p>MONTAPINE has been prescribed to you, by a doctor to relieve symptoms of Alzheimer&rsquo;s disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- Do not take MONTAPINE</strong></p><ul><li>If you are pregnant, unless in the opinion of the doctor, the expected benefit to the patient markedly outweighs the possible hazards to the fetus</li><li>You should not be taking MONTAPINE if you are breast-feeding.</li><li>Do not take MONTAPINE if you are allergic to it, or any of the other ingredients listed in this leaflet (see &lsquo;What the non-medicinal ingredients are&rsquo;)</li><li>Stop taking MONTAPINE if you experience an allergic reaction or any severe side effect.</li></ul><p>&nbsp;</p><p><strong>b- Warnings and Precautions</strong></p><p>Before starting MONTAPINE, talk to your doctor or pharmacist if:</p><ul><li>You have/had a medical condition, including heart problems, uncontrolled hypertension (high blood pressure), history of seizures or kidney disease</li><li>You have taken any medications (prescription or nonprescription) which you are taking or have taken within the last 14 days.</li><li>You ever had an allergic reaction to any medication</li><li>You are pregnant or thinking of becoming pregnant, or if you are breast-feeding.</li><li>There are conditions which can change the speed at which the body would normally eliminate the drug over time and you should tell your doctor, as MONTAPINE dosage may have to be adjusted if:</li><li>You have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet)</li><li>You are suffering from renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction [kidney problems])</li><li>You have a urinary tract infection</li></ul><p>&nbsp;</p><p><strong>c- Interactions with this medication</strong></p><p>Drugs that may interact with MONTAPINE include:</p><ul><li>NMDA-receptor antagonists (e.g.amantadine)</li><li>Cimetidine</li><li>Ranitidine</li><li>Procainamide</li><li>Quinidine</li><li>Quinine</li><li>Hydrochlorothiazide (or any combination with hydrochlorothiazide)</li><li>Anticholinergics (generally used to treat movement disorders or intestinal cramps)</li><li>L-dopa and dopaminergic agonists (drugs such as bromocriptine, ropinirole, pramipexole)</li><li>Ketamine</li><li>Dextromethorphan (found in cough syrup labeled DM)</li><li>Anticoagulant (blood thinner) medications taken by mouth</li></ul><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- How much MONTAPINE to take</strong><br />It is important that you take MONTAPINE exactly as your doctor has instructed. Usually your doctor will prescribe 20 mg per day, which you will take as two separate doses of 10 mg. In order to reduce the risk of side effects this dose will be achieved gradually by the following daily treatment scheme, starting at a dose of 5 mg per day.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td colspan="3" style="text-align:center"><strong>10mg</strong></td></tr><tr><td>&nbsp;</td><td><p>AM</p></td><td><p>PM</p></td></tr><tr><td><p>Week 1</p></td><td><p>1/2 tablet</p></td><td><p>None</p></td></tr><tr><td><p>Week 2</p></td><td><p>1/2 tablet</p></td><td><p>1/2 tablet</p></td></tr><tr><td><p>Week 3</p></td><td><p>1 tablet</p></td><td><p>1/2 tablet</p></td></tr><tr><td><p>Week 4 and beyond</p></td><td><p>1 tablet</p></td><td><p>1 tablet</p></td></tr></tbody></table><p>Never change the dose of MONTAPINE unless your doctor tells you to. Swallow the tablets, whole with some water. Do not chew tablets. MONTAPINE can be taken with or without food. Continue to take MONTAPINE as long as directed by your doctor and you do not experience any unacceptable side effects. Your doctor should assess your treatment on a regular basis.</p><p>&nbsp;</p><p><strong>b- If you take more MONTAPINE than you should</strong></p><p>If you have accidentally taken too much MONTAPINE, contact your regional Poison Control Centre, hospital emergency department or your doctor immediately, even if you do not feel sick. You may require medical attention. If you go to the doctor or the hospital, take MONTAPINE container with you.</p><p>&nbsp;</p><p><strong>c- If you forget to take MONTAPINE</strong></p><p>If you miss a dose, do not worry. Do not take the missed tablet(s) - just take the next dose when it is due.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, MONTAPINE can cause side effects, although not everybody gets them. In general, these are mild to moderate. If any of the side effects become severe or if they are troublesome or persistent, talk to your doctor.</p><p><strong>Common side effects (affects 1 to 10 users in 100) may include:</strong></p><p>&bull; headache<br />&bull; sleepiness<br />&bull; constipation<br />&bull; tiredness<br />&bull; confusion<br />&bull; hallucinations (strange visions or sounds)<br />&bull; vomiting<br />&bull; loss of appetite<br />&bull; dizziness<br />&bull; sleep disturbance<br />&bull; anxiety<br />&bull; high blood pressure<br />&bull; change in frequency of urination</p><p>&nbsp;</p><p><strong>Uncommon side effects (affects 1 to 10 users in 1000) may include:</strong></p><p>&bull; fungal infections<br />&bull; changes in vision.&nbsp;</p><p>Your doctor will tell you whether your illness allows you to drive or operate machinery. Also, as this product may cause sleepiness or dizziness, do not drive or operate machinery under these conditions. Alzheimer&rsquo;s disease has been associated with depression, thoughts of suicide and suicide. These events have been reported in patients treated with MONTAPINE. If you have previously experienced epileptic seizures, there is a possibility that MONTAPINE may increase the chances of one occurring.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p style="text-align:center"><strong>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td colspan="2" rowspan="2" style="width:419px"><p><strong>Symptom/Effect</strong></p></td><td colspan="2" style="vertical-align:top; width:51px"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Stop taking drug and call your doctor or pharmacist</strong></p></td></tr><tr><td style="vertical-align:top; width:1px"><p><strong>Only if severe</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>In all cases</strong></p></td></tr><tr><td rowspan="4" colspan="1"><p><strong>Uncommon</strong></p></td><td style="width:333px"><p>Fungal infection</p></td><td style="width:1px"><p>✔</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="width:333px"><p>Abnormal gait [Abnormal way of walking]</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="width:333px"><p>Heart failure [persistent chest pain, rapid heart rate, severe shortness of breath, swelling of legs or ankles,<br />increased tiredness, lack of appetite, confusion]</p></td><td style="width:1px">&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="width:333px"><p>Venous blood clotting [pain, swelling, changes in skin color, increased warmth in one leg]</p></td><td style="width:1px">&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td rowspan="4" colspan="1"><p><strong>Very Rare</strong></p></td><td style="width:333px"><p>Seizures [loss of consciousness with uncontrollable shaking]</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="width:333px"><p>Hepatitis/hepatic failure [yellow skin and eyes, nausea, loss of appetite, dark coloured urine]</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="width:333px"><p>Serious skin reactions [rash, red skin, blistering of the lips, eyes or mouth, skin peeling]</p></td><td style="width:1px">&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="width:333px"><p>Psychotic reactions</p></td><td style="width:1px">&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top"><p>✔</p></td></tr></tbody></table><p>This is not a complete list of side effects. For any unexpected effects while taking MONTAPINE,<br />contact your doctor or pharmacist. If you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>As with all medicines, keep MONTAPINE out of the reach of children.</li><li>Store your tablets below 30&deg;C.</li><li>If your doctor tells you to stop taking your medicine you should return any leftover tablets to the pharmacist unless the doctor tells you to keep them at home.</li></ul><p>REMEMBER: This medicine is for YOU or for someone in your care. Only a doctor can prescribe it, so never offer it to any other person, even if their symptoms seem to be the same as yours or as for the person in your care.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- What the medicinal ingredient is</strong></p><p>Memantine hydrochloride.</p><p>&nbsp;</p><p><strong>b- What the non-medicinal ingredients are</strong></p><p>Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
White, peanut shaped, biconvex film coated tablet of 10mg strength. Engraved “APO” bisect “APO” on one side, “MEM”
bisect “10” on the other side.
Marketed in blisters of 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 03/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي المخ على مستقبلات مادة أن-ميثيل-دي-أسبارتيت (أن أم دي أيه) المسؤولة عن نقل الإشارات العصبية والتي قد تكون مهمة للتعلم والذاكرة. وقد يؤثر النقل غير السوي للإشارات العصبية من خلال مستقبلات &quot;أن أم دي أيه&quot; في المخ على الذاكرة والوظائف الذهنية الأخرى ويساهم في ظهور أعراض مرض الزهايمر. ينتمي الدواء مونتابين إلى فئة من الأدوية تُسمى مناهضات مستقبلات &quot;أن أم دي أيه&quot;. يمكن أن يساعد مفعول مونتابين تجاه مستقبلات &quot;أن أم دي أيه&quot; على تحسين نقل الإشارات العصبية إلى الوضع الطبيعي، مما يساعد في تقليل تفاقم بعض أعراض مرض الزهايمر.</p><p>لقد وصف لك الطبيب الدواء مونتابين لتخفيف أعراض مرض الزهايمر.<br />&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لا يؤخذ الدواء مونتابين في الحالات التالية:</strong></p><ul><li>في حالة الحمل، إلا إذا رأى الطبيب أن الفوائد المتوقعة للمريض تفوق بوضوح المخاطر المحتملة على الجنين</li><li>ينبغي عدم استخدام مونتابين في حالة الرضاعة الطبيعية.</li><li>لا يؤخذ مونتابين في حالة الحساسية تجاه المادة الفعالة فيه، أو أيٍ من المكونات الأخرى المذكورة في هذه النشرة (انظر القسم &quot;ما هي المكونات غير الدوائية في هذا الدواء&quot;)</li><li>ينبغي التوقف عن تناول مونتابين في حالة حدوث رد فعل تحسسي أو أي آثار جانبية خطيرة.</li></ul><p>&nbsp;</p><p><strong>ب- التحذيرات والاحتياطات</strong></p><p>قبل البدء في تناول مونتابين، ينبغي استشارة الطبيب أو الصيدلي في الحالات التالية:</p><ul><li>إذا كنت تعاني من أي حالة طبية بما في ذلك المشكلات القلبية وضغط الدم غير المنتظم (المرتفع) أو تاريخ من نوبات صرع أو مرض كلوي،</li><li>إذا كنت تتناول أي أدوية (سواء أخذتها بوصفة طبية أم بدونها) خلال آخر 14 يومًا.</li><li>إذا كنت قد أُصبت برد فعل تحسسي تجاه أي دوء قبل ذلك.</li><li>في حالة حدوث حمل أو التفكير في الحمل أو الرضاعة الطبيعية.</li><li>هناك حالات يمكن أن تتغير فيها سرعة تخلص الجسم من الدواء بشكل طبيعي بمرور الوقت، وينبغي إخبار الطبيب بأي شيء غير معتاد لديك لأنه قد يلزم تغيير جرعة مونتابين في الحالات التالية:</li><li>إذا قمت بتغيير نظامك الغذائي بشكل كبير مؤخرًا أو إذا كنت تنوي فعل ذلك (مثلاً التحويل من نظام غذائي عادي إلى نظام غذائي نباتي صارم)</li><li>إذا كنت تعاني من الحماض الأنبوبي الكلوي (آر تي أيه، زيادة مواد تكوين الأحماض في الدم بسبب الفشل الكلوي [مشكلات في الكلى])</li><li>الإصابة بعدوى في المسالك البولية</li></ul><p>&nbsp;</p><p><strong>ج- التفاعلات مع هذا الدواء</strong></p><p>الأدوية التي يمكن أن تتفاعل مع مونتابين تشمل:<br />&bull; مناهضات مستقبلات &quot;أن أم دي أيه&quot; (مثل أمانتادين)<br />&bull; سيمتدين<br />&bull; رانيتدين<br />&bull; بروكاييناميد<br />&bull; كينيدين<br />&bull; كينين<br />&bull; هيدروكلورثيازيد (أو أي دواء يؤخذ مع هيدروكلورثيازيد)<br />&bull; مضادات الفعل الكوليني (أدوية تُستخدم عمومًا لعلاج اضطرابات الحركة أو التقلصات المعوية)<br />&bull; أل-دوبا ومنبهات الدوبامين (الأدوية مثل بروموكريبتين، روبينيرول، براميبكسول)<br />&bull; كيتامين<br />&bull; ديكستروميثورفان (يوجد في أدوية السعال المميزة بحرفي DM)<br />&bull; الأدوية المضادة للتخثر (مرققات الدم) التي تؤخذ عن طريق الفم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- مقدار جرعة مونتابين</strong></p><p>من المهم تناول جرعة مونتابين حسب تعليمات الطبيب تمامًا. عادةً سيصف لك الطبيب تناول 20 ملجم في اليوم، وسوف تأخذها على جرعتين منفصلتين كل منهما 10 ملجم. وذلك من أجل تخفيف مخاطر الآثار الجانبية التي ستنشأ عن هذه الجرعة بشكل تدريجي مع الالتزام بالخطة العلاجية اليومية، مع البدء بجرعة 5 ملجم في اليوم</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td colspan="3" style="text-align:center"><strong>أقراص ۱۰ ملجم</strong></td></tr><tr><td><p>&nbsp;</p></td><td><p>صباحًا</p></td><td><p>مساءً</p></td></tr><tr><td><p>الأسبوع الأول</p></td><td><p>&frac12;&nbsp;قرص</p></td><td><p>لا يوجد</p></td></tr><tr><td><p>الأسبوع الثاني</p></td><td><p>&nbsp;&frac12;&nbsp;قرص</p></td><td><p>&frac12;&nbsp;قرص</p></td></tr><tr><td><p>الأسبوع الثالث</p></td><td><p>قرص واحد</p></td><td><p>&frac12;&nbsp;قرص</p></td></tr><tr><td><p>الأسبوع الرابع وما بعده</p></td><td><p>قرص واحد</p></td><td><p>قرص واحد</p></td></tr></tbody></table><p>يجب عدم تغيير جرعة مونتابين ما لم يخبرك الطبيب بذلك. ابتلع القرص كاملاً مع بعض الماء. لا تمضغ القرص. يمكن تناول أقراص مونتابين مع الطعام أو بدون الطعام. ينبغي الاستمرار في تناول أقراص مونتابين ما دام الطبيب يخبرك بذلك وما دمت لا تعاني من أي آثار جانبية غير محتملة. ينبغي أن يقوم الطبيب بتقييم علاجك بصفة منتظمة.</p><p>&nbsp;</p><p><strong>ب- في حالة تناول جرعة زائدة من مونتابين أكثر من الموصى بها</strong></p><p>في حالة تناول جرعة كبيرة جدًا من أقراص مونتابين عن طريق الخطأ، اتصل على الفور بمركز مكافحة السموم الإقليمي لديك أو قسم الطوارئ بالمستشفى أو بالطبيب، حتى لو لم تشعر بالإعياء. قد تحتاج إلى رعاية طبية. عند الذهاب إلى الطبيب أو المستشفىن خذ معك حاوية الدواء مونتابين.</p><p>&nbsp;</p><p><strong>ج- في حالة نسيان تناول جرعة مونتابين</strong></p><p>في حالة نسيان جرعة، لا تقلق. لا تتناول القرص المنسي، وإنما تناول الجرعة التالية عندما يحين موعدها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن أن يسبب مونتابين آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه. عمومًا، تكون الأعراض الجانبية خفيفة إلى معتدلة. في حالة تفاقم خطورة أيٍ من الآثار الجانبية أو استمرارها بشكل مزعج، ينبغي استشارة الطبيب.</p><p>&nbsp;</p><p><strong>يمكن أن تشمل الآثار الجانبية الشائعة (تؤثر في شخص واحد إلى 10 أشخاص من كل 100 شخص يستخدمون هذا الدواء) ما يلي:</strong><br />&bull; صداع<br />&bull; نعاس<br />&bull; إمساك<br />&bull; تعب<br />&bull; ارتباك<br />&bull; هلوسات (رؤية أشياء غريبة أو أصوات)<br />&bull; قيء<br />&bull; فقدان الشهية<br />&bull; دوار<br />&bull; اضطراب النوم<br />&bull; قلق<br />&bull; ارتفاع ضغط الدم<br />&bull; تغير في مرات التبول</p><p>&nbsp;</p><p><strong>يمكن أن تشمل الآثار الجانبية غير الشائعة (تؤثر في شخص واحد إلى 10 أشخاص من كل 1000 شخص يستخدمون هذا الدواء) ما يلي:</strong><br />&bull; التهابات فطرية<br />&bull; تغيرات في الرؤية.&nbsp;</p><p>سوف يخبرك الطبيب ما إذا كانت حالتك الطبية تسمح بقيادة سيارات أو تشغيل آلات أم لا. علاوة على ذلك، قد يسبب هذا الدواء نعاسًا أو دوارًا، ولذا ينبغي تجنب قيادة مركبات أو تشغيل آلات في حالة الشعور بنعاس أو دوار. وقد ارتبط مرض الزهايمر بالاكتئاب والتفكير في الانتحار ومحاولة الانتحار. وقد تم الإبلاغ عن هذه الحالات في مرضى يُعالجون بالدواء مونتابين. إذا كنت قد أُصبت سابقًا بنوبات صرع، فمن المحتمل أن يؤدي مونتابين إلى زيادة فرص حدوث تلك النوبات.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td colspan="2" rowspan="2" style="width:334px"><p dir="RTL"><strong>العرض/الآثر</strong></p></td><td colspan="2" style="width:169px"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td rowspan="2" style="width:110px"><p dir="RTL"><strong>توقف عن تناول الدواء واتصل بالطبيب أو الصيدلي</strong></p></td></tr><tr><td style="width:88px"><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td style="width:81px"><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td rowspan="4" colspan="1"><p dir="RTL"><strong>غير شائعة</strong></p></td><td style="width:262px"><p dir="RTL">الالتهاب الفطري</p></td><td style="width:88px"><p dir="RTL">✔</p></td><td style="width:81px"><p>&nbsp;</p></td><td style="width:110px"><p>&nbsp;</p></td></tr><tr><td style="width:262px"><p dir="RTL">مشية غير سوية [طريقة مشي غير طبيعية]</p></td><td style="width:88px"><p dir="RTL">&nbsp;</p></td><td style="width:81px"><p>✔</p></td><td style="width:110px"><p>&nbsp;</p></td></tr><tr><td style="width:262px"><p dir="RTL">فشل القلب [ألم مستمر في الصدر، سرعة نبض القلب، قصر نفس حاد، تورم الساقين أو الكاحلين، تعب زائد، نقص الشهية، ارتباك]</p></td><td style="width:88px"><p>&nbsp;</p></td><td style="width:81px"><p dir="RTL">&nbsp;</p></td><td style="width:110px"><p>✔</p></td></tr><tr><td style="width:262px"><p dir="RTL">جلطة دموية وريدية [ألم، تورم، تغيرات في لون الجلد، سخونة زائدة في إحدى الساقين]</p></td><td style="width:88px"><p>&nbsp;</p></td><td style="width:81px"><p dir="RTL">&nbsp;</p></td><td style="width:110px"><p>✔</p></td></tr><tr><td colspan="1" rowspan="4"><p><strong>نادرة جدًا</strong></p></td><td style="width:262px"><p>نوبات صرع [فقدان الوعي مع ارتجاج غير قابل للسيطرة]</p></td><td style="width:88px">&nbsp;</td><td style="width:81px">&nbsp;</td><td style="width:110px"><p>✔</p></td></tr><tr><td style="width:262px"><p>ردود فعل خطيرة في الجلد [طفح، احمرار الجلد، تنفط الشفتين أو العينين أو الفم، تقشر الجلد]</p></td><td style="width:88px">&nbsp;</td><td style="width:81px">&nbsp;</td><td style="width:110px"><p>✔</p></td></tr><tr><td style="width:262px"><p>التهاب البنكرياس [ألم شديد في أعلى البطن<br />ومصحوب غالبًا بغثيان وقيء]</p></td><td style="width:88px">&nbsp;</td><td style="width:81px">&nbsp;</td><td style="width:110px"><p>✔</p></td></tr><tr><td style="width:262px"><p>ردود فعل نفسية</p></td><td style="width:88px">&nbsp;</td><td style="width:81px">&nbsp;</td><td style="width:110px"><p>✔</p></td></tr></tbody></table><p>وهذه ليست قائمة كاملة بكل الآثار الجانبية. وفي حالة حدوث أي آثار غير متوقعة أثناء تناول الدواء مونتابين</p><p>يُرجى الاتصال بالطبيب أو الصيدلي. في حالة ملاحظة أي آثار جانبية أخر ى غير المذكورة في هذه النشرة، يُرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; كما هو الحال مع جميع الأدوية، يُحفظ مونتابين عن متناول الأطفال.</p><p>&bull; تُحفظ الأقراص في درجة حرارة أقل من 30 درجة مئوية.</p><p>&bull; إذا طلب منك الطبيب التوقف عن تناول الدواء، ينبغي إعادة أي أقراص متبقية إلى الصيدلي ما لم يخبرك بالاحتفاظ بها في المنزل.</p><p>تذكر: إن هذا الدواء مخصص لك أو لشخص تحت رعايتك. إن هذا الدواء لا يوصف إلا بأمر الطبيب، لذا لا تقدمه لأي شخص آخر حتى لو كانت الأعراض التي يعاني منها ذلك الشخص تتشابه مع تلك التي تعاني أنت منها أو الشخص الذي تحت رعايتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- ما هو المكون الدوائي؟</strong></p><p>ميمانتين هيدروكلوريد.</p><p>&nbsp;</p><p><strong>ب- ما هي المكونات غير الدوائية؟</strong></p><p>لاكتوز مونوهيدرات، سليولوز دقيق البلورات، كروسكارميلوز صوديوم، ستيرات الماغنيسيوم، هيدروكسي بروبيل سيلولوز، هيدروكسي بروبيل ميثيل سيلولوز، بولي ايثيلين جلايكول وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص 10 ملجم بيضاء اللون متحدبة الجوانب ومغلفة محفور عليها &laquo;APO&raquo; فوق &laquo;APO&raquo; من جانب و &laquo;MEM&raquo; فوق &laquo;10&raquo; على الجانب الآخر.<br />تباع&nbsp;في عبوات بها شرائط تحتوي على 30 قرصاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Names: MONTAPINE (Saudi Arabia)/Apo-Memantine Generic Name: Memantine HCL
Dosage Form: Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-MEMANTINE tablets contain 10 mg of memantine hydrochloride and the following non- medicinal ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, and titanium dioxide. For a detailed composition, see Table in Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White, peanut shaped, biconvex film coated tablet. Engraved "APO" bisect "APO" on one side, "MEM" bisect"10" on the other side.

Type of Container and Enclosure used for Dosage Form:

Blister packs of 30 comprising of silver plain foil and clear PVC/PVDC film.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-MEMANTINE is an N-methyl-D-aspartate (NMDA) receptor antagonist</p><p>APO-MEMANTINE (memantine hydrochloride) may be useful as monotherapy for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer&rsquo;s type.</p><p>APO-MEMANTINE tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer&rsquo;s disease.</p><p>In a 28-week placebo controlled monotherapy trial, patients with moderate to severe Alzheimer&rsquo;s disease showed stabilization or less worsening of functional and cognitive symptoms and of global assessment when treated with memantine hydrochloride compared to placebo.</p><p>Memantine hydrochloride has not been studied in controlled clinical trials for the symptomatic treatment of moderate to severe Alzheimer&rsquo;s disease for more than 6 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-MEMANTINE (memantine hydrochloride) should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer&rsquo;s disease. Therapy should only be started if a caregiver is available who will regularly monitor drug intake by the patient. Diagnosis should be made according to current guidelines.</p><p><em>Adults: </em>The recommended maintenance dose for memantine is 20 mg/day. In order to reduce the risk of side effects the maintenance dose is achieved by upward titration as follows: the usual starting dose is 5 mg/day. The dose should then be increased in 5 mg increments to 10 mg/day (5 mg twice a day), 15 mg/day (10 mg and 5 mg as separate doses), and 20 mg/day (10 mg twice a day), depending on the patient&rsquo;s response and tolerability. The minimum recommended interval between dose increases is one week. The recommended dose titration is summarized in the following table.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>10 mg Tablets</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AM</p></td><td style="vertical-align:top"><p>PM</p></td></tr><tr><td style="vertical-align:top"><p>Week 1</p></td><td style="vertical-align:top"><p>&frac12; tablet</p></td><td style="vertical-align:top"><p>none</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>&frac12; tablet</p></td><td style="vertical-align:top"><p>&frac12; tablet</p></td></tr><tr><td style="vertical-align:top"><p>Week 3</p></td><td style="vertical-align:top"><p>1 tablet</p></td><td style="vertical-align:top"><p>&frac12; tablet</p></td></tr><tr><td style="vertical-align:top"><p>Week 4 and beyond</p></td><td style="vertical-align:top"><p>1 tablet</p></td><td style="vertical-align:top"><p>1 tablet</p></td></tr></tbody></table><p>The tablets can be taken with or without food.</p><p>&nbsp;</p><p><strong>SPECIAL POPULATIONS</strong></p><p><em>Elderly: </em>On the basis of the clinical studies the recommended dose for patients over the age of 65 years is 20 mg per day (10 mg twice a day) as described above (see 5.2).</p><p>&nbsp;</p><p><em>Renal impairment: </em>In patients with mildly impaired renal function (creatinine clearance 50-80 ml/min) no dosage adjustment is required. In patients with moderate renal impairment (creatinine clearance 30-49 ml/min) the daily dose should be 10 mg per day. If well tolerated after at least 7 days of treatment, and based on clinical response, the dose may be increased up to 20 mg/day according to the standard titration scheme. In patients with severe renal impairment (creatinine clearance 15-29 ml/min) the daily dosage should be 10 mg per day (see 5.2 and 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment: </em>In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B) no dose adjustment is needed (see 5.2). There are no data available for use of memantine in patients with severe hepatic impairment. Therefore, administration of APO- MEMANTINE is not recommended in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-MEMANTINE (memantine hydrochloride) is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>NEUROLOGICAL</strong><strong> CONDITIONS</strong></p><p>Seizures: memantine hydrochloride has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the premarketing testing of memantine hydrochloride. In clinical trials, seizures occurred in 0.3% of patients treated with memantine hydrochloride and 0.4% of patients treated with placebo. Seizure activity may be a manifestation of Alzheimer&rsquo;s disease. The risk/benefit of memantine treatment for patients with a history of seizure disorder or predisposing factors for epilepsy must therefore be carefully evaluated.</p><p>&nbsp;</p><p><strong>GENITOURINARY CONDITIONS</strong></p><p>Conditions that raise urine pH may reduce the urinary elimination of memantine by a factor of 7 to 9, resulting in increased plasma levels of memantine (see 5.4). These conditions include drastic changes in diet, e.g. from a carnivore to a vegetarian diet, or a massive ingestion of alkalising gastric buffers (see Drugs Which Makes Urine Alkaline, 4.4). Also, urine pH may be elevated by states of renal tubulary acidosis (RTA) or severe infections of the urinary tract with <em>Proteus bacteria</em>.</p><p>&nbsp;</p><p><strong>CARDIOVASCULAR CONDITIONS</strong></p><p>In most clinical trials, patients with recent myocardial infarction, uncompensated congestive heart failure (NYHA III-IV), and uncontrolled hypertension were excluded. However, patients such as those with controlled hypertension (DBP &lt; 105 mm/Hg), right bundle branch blockage and pacemaker were included. Although cardiovascular adverse events occurred at low frequencies in the two placebo-controlled clinical trials involving patient with moderate to severe Alzheimer&rsquo;s disease, there were increased frequencies of hypertension, chest pain, bradycardia and cardiac failure adverse events in patients who were treated with memantine hydrochloride compared to placebo in these trials. Consequently, caution should be observed when memantine is initiated in patients with cardiovascular conditions.</p><p>&nbsp;</p><p><strong>PRECAUTIONS OPHTHALMIC CONDITIONS</strong></p><p>In an open label study where memantine hydrochloride was administered to 10 elderly patients at a dose of 20 mg per day for approximately 48 months, memantine concentrations in lacrimal fluid were about 3 fold higher than in plasma and did not show ophthalmologic effects. In another 6-month placebo-controlled trial, no major treatment differences were reported for ocular effects but worsening of the corneal condition was reported for slightly more patients treated with memantine hydrochloride than placebo (5.4% memantine vs. 3.3% placebo). Repeat-dose toxicology studies demonstrated corneal and lens histopathological changes in rodents treated with&nbsp; memantine hydrochloride.&nbsp; Therefore, periodic monitoring of the patient&rsquo;s ophthalmic condition is recommended.</p><p>&nbsp;</p><p><strong>CONCOMITANT USE WITH OTHER DRUGS</strong></p><p><em>Use </em><em>with compounds chemically related to N-methyl-D-aspartate (NMDA) antagonists: </em>As these compounds act at the same receptor system as memantine, adverse drug reactions (mainly CNS- related) may be more frequent or pronounced. Pharmacotoxic psychosis has been reported in the literature in two Parkinson&rsquo;s disease patients who were treated concomitantly with memantine, amantadine, L-dopa and terguride (see 4.4, Drug Interactions, Other agents). The combined use of memantine hydrochloride with other compounds chemically related to NMDA antagonists such as amantadine, ketamine or dextromethorphan has not been systematically evaluated and is therefore not recommended.</p><p>&nbsp;</p><p><strong>CONDITIONS THAT MAKE URINE ALKALINE</strong></p><p>The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions (see 5.2 and 4.4).</p><p>&nbsp;</p><p><strong><u>SPECIAL POPULATIONS</u> </strong></p><p><strong>HEPATIC IMPAIRMENT</strong></p><p>Memantine hydrochloride undergoes minimal hepatic metabolism and is excreted primarily in its unchanged form by the kidneys. The pharmacokinetics of memantine have been studied in subjects with moderate hepatic impairment (see 5.2). In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B) no dose adjustment is needed. There are no data available for use of memantine in patients with severe hepatic impairment. Therefore, administration of memantine hydrochloride is not recommended in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><strong>RENAL IMPAIRMENT</strong></p><p>In patients with mildly impaired renal function (creatinine clearance 50-80 ml/min) no dosage adjustment is required. In patients with moderate renal impairment (creatinine clearance 30-49 ml/min) the daily dose should be 10 mg per day. If well tolerated after at least 7 days of treatment, and based on clinical response, the dose may be increased up to 20 mg/day according to the standard titration scheme. In patients with severe renal impairment (creatinine clearance 15-29 ml/min) the daily dosage should be 10 mg per day (see 5.2 and 4.2).</p><p>&nbsp;</p><p><strong>USE IN PATIENTS &ge; 85 YEARS OLD</strong></p><p>In placebo-controlled clinical studies, the number of patients aged 85 years or older who received memantine at the therapeutic dose of 20 mg/day was 40. There is limited safety information for memantine hydrochloride in this patient population.</p><p>&nbsp;</p><p><strong>USE IN PATIENTS WITH SERIOUS CO-MORBID CONDITIONS.</strong></p><p>There is limited information on the safety of memantine treatment in patients with moderate to severe Alzheimer&rsquo;s disease with serious co-morbidities, as these patients were excluded from clinical trials. The use of memantine hydrochloride in Alzheimer&rsquo;s disease patients with chronic illnesses common among the geriatric population should be considered only after a proper risk/benefit assessment. Dose escalation in this patient population should proceed with caution.</p><p>&nbsp;</p><p><strong>PREGNANCY</strong></p><p>Oral treatment of female rats with memantine once daily during organogenesis produced mild maternal toxicity at doses of 6-18 mg/kg/day (3-9 times the Maximum Recommended Human Dose [MRHD] on a mg/m2&nbsp;basis); however, memantine was not teratogenic at doses up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis), the highest dose tested. In a rat reproduction and fertility study, reduced growth and a developmental delay were observed at 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis).</p><p>Memantine doses of 0, 3, 10 and 30 mg/kg/day were orally administered to pregnant rabbits during the period of organogenesis. At 30 mg/kg/day (30 times the MRHD on a mg/m2&nbsp;basis) maternal toxicity and a slight increase in post-implantation loss were observed. No teratogenic effects were observed in rabbits administered memantine 30 mg/kg/day (30 times the MRHD on a mg/m2&nbsp;basis). The maternal and fetal no observed effect level (NOEL) was 10 mg/kg/day (10 times the MRHD on a mg/m2&nbsp;basis).</p><p>In a peri and postnatal study, memantine was orally administered to rats at up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis). At 18 mg/kg/day pups showed reduced mean body weights but there was no effect on their development or behaviour. Animal studies showed no indication of an adverse effect of memantine on labour and delivery.</p><p>There are no adequate and well-controlled studies of memantine in pregnant women to establish the safe use of memantine hydrochloride for this population. Therefore, memantine hydrochloride should not be used in women of childbearing potential, unless, in the opinion of the physician, the expected benefits to the patient markedly outweigh the possible hazards to the fetus.</p><p>&nbsp;</p><p><strong>NURSING MOTHERS</strong></p><p>It is not known whether memantine is excreted in human breast milk. Therefore, memantine hydrochloride should not be used in nursing mothers.</p><p>&nbsp;</p><p><strong>PEDIATRIC USE</strong></p><p>The safety and effectiveness of memantine hydrochloride in any illness occurring in pediatric patients have not been established. Therefore, memantine hydrochloride is not recommended for use in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DRUG</strong><strong> </strong><strong>INTERACTIONS</strong></p><p><em>Compounds</em><em> chemically related to N-methyl-D-aspartate (NMDA) antagonists: </em>The combined use of memantine hydrochloride with other compounds chemically related to NMDA antagonists such as amantadine, ketamine or dextromethorphan has not been systematically evaluated and is therefore not recommended (see 4.4, Concomitant Use With Other Drugs).</p><p><em>Effects</em><em> o</em>f <em>memantine </em><em>hydrochloride on substrates of microsomal enzymes: In vitro </em>studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, - 3A4) revealed minimal inhibition of these enzymes by memantine. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected.</p><p><em>Effects</em><em> of inhibitors and/or substrates of microsomal enzymes on memantine hydrochloride: </em>Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.</p><p><em>Acetylcholinesterase</em><em> </em><em>(AChE)</em><em> </em><em>inhibitors: In vitro </em>studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil or galantamine.</p><p><em>Drugs eliminated via renal mechanisms: </em>Co-administration of drugs that use the same renal cationic transport system as memantine, such as cimetidine, ranitidine, quinidine, hydrochlorothiazide (HCTZ), triamterene (TA), and nicotine could potentially alter the plasma levels of both agents. Co-administration of memantine hydrochloride and hydrochlorothiazide/triamterene (HCTZ/TA) did not affect the bioavailability of either memantine or triamterene, and the bioavailability of HCTZ decreased by 20%. The pharmacokinetics of memantine is similar in smokers and non-smokers, suggesting that nicotine may not affect the disposition of memantine<em>.</em><em> </em>The potential for compromised renal function in elderly patients should be considered when memantine will be used concomitantly with other drugs eliminated via renal mechanisms (see 4.4, 4.2).</p><p><em>Drugs highly bound to plasma proteins: </em>Because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely.</p><p><em>Oral Anticoagulants: </em>In post marketing experience isolated cases of international normalized ratio (INR) increases have been reported in patients treated concomitantly with memantine and warfarin. Although no causal relationship has been established, close monitoring of prothrombin time or INR is advised for patients treated concomitantly with memantine and oral anticoagulants.</p><p><em>Anti-hyperglycemic drugs: </em>In young healthy adult subjects (n=21, age range 19-35 years), co- administration of a single 20 mg oral dose of memantine under steady state conditions of glyburide/metformin (1.25 mg glyburide/250 mg metformin) did not affect the pharmacokinetics of memantine, glyburide or metformin. The renal excretion of metformin and memantine, and potential for compromised renal function in elderly patients should be considered when memantine and metformin will be used concomitantly (see 4.4, 4.2).</p><p><em>Other agents</em>: Since the effects of L-dopa, dopaminergic agonists, and anti-cholinergics may be enhanced by concomitant treatment with memantine hydrochloride, dosage adjustment of these other agents may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>PREGNANCY</strong></p><p>Oral treatment of female rats with memantine once daily during organogenesis produced mild maternal toxicity at doses of 6-18 mg/kg/day (3-9 times the Maximum Recommended Human Dose [MRHD] on a mg/m2&nbsp;basis); however, memantine was not teratogenic at doses up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis), the highest dose tested. In a rat reproduction and fertility study, reduced growth and a developmental delay were observed at 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis).</p><p>Memantine doses of 0, 3, 10 and 30 mg/kg/day were orally administered to pregnant rabbits during the period of organogenesis. At 30 mg/kg/day (30 times the MRHD on a mg/m2&nbsp;basis) maternal toxicity and a slight increase in post-implantation loss were observed. No teratogenic effects were observed in rabbits administered memantine 30 mg/kg/day (30 times the MRHD on a mg/m2&nbsp;basis). The maternal and fetal no observed effect level (NOEL) was 10 mg/kg/day (10 times the MRHD on a mg/m2&nbsp;basis).</p><p>In a peri and postnatal study, memantine was orally administered to rats at up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis). At 18 mg/kg/day pups showed reduced mean body weights but there was no effect on their development or behaviour. Animal studies showed no indication of an adverse effect of memantine on labour and delivery.</p><p>There are no adequate and well-controlled studies of memantine in pregnant women to establish the safe use of memantine hydrochloride for this population. Therefore, memantine hydrochloride should not be used in women of childbearing potential, unless, in the opinion of the physician, the expected benefits to the patient markedly outweigh the possible hazards to the fetus.</p><p>&nbsp;</p><p><strong>NURSING MOTHERS</strong></p><p>It is not known whether memantine is excreted in human breast milk. Therefore, memantine hydrochloride should not be used in nursing mothers.</p><p>&nbsp;</p><p><strong>CARCINOGENESIS,</strong><strong> </strong><strong>MUTAGENESIS</strong><strong> AND IMPAIRMENT OF FERTILITY.</strong></p><p>There was no evidence of carcinogenicity in a 113-week oral study in mice for either sex at doses up to 40 mg/kg/day (10 times the maximum recommended human dose [MRHD] on a mg/m2&nbsp;basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (19 and 10 times the MRHD on a mg/m2 basis, respectively) through 128 weeks.</p><p>Memantine did not show any genotoxic potential in assays for gene mutation (bacterial and mammalian cells <em>in vitro</em>) or in clastogenicity assays (human lymphocytes <em>in vitro </em>and mouse bone marrow <em>in vivo</em>).</p><p>No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doctors should advise their patients whether their illness allows them to drive or operate machinery. Also, as this product may cause sleepiness or dizziness, patients should not drive or operate machinery under these conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A total of 916 patients were treated with memantine in double-blind, placebo-controlled dementia studies. Of these patients, 726 (79%) completed the studies. Patients were treated with memantine for a mean of 148.5 days. Approximately 61% of patients received memantine for at least 24 weeks.</p><p>&nbsp;</p><p><strong>Adverse Events Leading to Discontinuation of Treatment: </strong>In placebo-controlled trials in which dementia patients received doses of memantine hydrochloride up to 20 mg/day, 11.1 % (102/916) of the memantine hydrochloride-treated patients discontinued treatment due to an adverse event. The discontinuation rate in the placebo-treated patients was 11.6% (109/893). The most frequent adverse event leading to discontinuation was agitation with an observed frequency among patients who discontinued treatment of 1.0% in patients receiving memantine vs. 1.8% in patients administered placebo. None of the other adverse events leading to discontinuation met the criteria for most common adverse events, defined as those occurring at a frequency of at least 2% and at twice the incidence seen in placebo patients.</p><p>&nbsp;</p><p><strong>Adverse Events Reported in Placebo-Controlled Dementia Trials: </strong>Table 1 lists treatment emergent signs and symptoms that were reported in at least 2% of patients in placebo-controlled dementia trials and for which the rate of occurrence was greater for patients treated with memantine hydrochloride than for those treated with placebo. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the &nbsp;relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied.</p><p>&nbsp;</p><p><strong>Table 1: Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Memantine hydrochloride and at a Higher Frequency than Placebo-treated Patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System </strong></p><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>(N=893)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Memantine hydrochloride </strong></p><p><strong>(N=916)</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Body as a Whole</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular System</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Central and Peripheral Nervous System</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>5.5</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>4.5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal System</strong></p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoae</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal System</strong></p></td></tr><tr><td style="vertical-align:top"><p>Back Pain</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Confusion</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>4.6</p></td></tr><tr><td style="vertical-align:top"><p>Hallucinations</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory System</strong></p></td></tr><tr><td style="vertical-align:top"><p>Coughing</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>3.4</p></td></tr></tbody></table><p>Other adverse events occurring with an incidence of at least 2% in memantine hydrochloride- treated patients but at an equal or lower rate than placebo were agitation, arthralgia, bronchitis, cataract, depression, fall, gait abnormal, inflicted injury, influenza-like symptoms, insomnia, urinary incontinence and urinary tract infection.</p><p>&nbsp;</p><p><strong>Vital Sign Changes: </strong>Memantine hydrochloride and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with memantine hydrochloride treatment.</p><p>&nbsp;</p><p><strong>Laboratory Changes: </strong>Memantine hydrochloride and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with memantine hydrochloride treatment.</p><p>&nbsp;</p><p><strong>ECG Changes: </strong>Memantine hydrochloride and placebo groups were compared with respect to (1) mean change from baseline in various ECG parameters and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in ECG parameters associated with memantine hydrochloride treatment.</p><p>&nbsp;</p><p><strong>Other Adverse Events Observed During Clinical Trials</strong></p><p>Memantine hydrochloride has been administered to approximately 1333 patients with dementia, of whom more than 1200 received the maximum recommended dose of 20 mg/day.</p><p>Approximately 830 patients received memantine hydrochloride for at least 6 months of treatment and 387 patients were treated for approximately a year or more.</p><p>All adverse events occurring in at least two patients are included, except for those already listed in Table 1, WHO terms too general to be informative, or events unlikely to be caused by the drug. Also included are the adverse events observed in the placebo-controlled trial in patients who had been previously treated with donepezil prior to memantine hydrochloride treatment.</p><p>Events are classified by body system and listed using the following definitions: <em>frequent</em><em> </em>&ndash; those occurring on one or more occasions in at least 1/100 patients; <em>infrequent</em>&ndash; those occurring in less than 1/100 patients but at least in 1/1000 patients. These adverse events are not necessarily related to memantine hydrochloride treatment and in most cases were observed at a similar frequency in placebo-treated patients in the controlled studies.</p><p>&nbsp;</p><p><strong>Autonomic Nervous</strong><strong> System: </strong><em>Infrequent: </em>sweating increased, mouth dry.</p><p>&nbsp;</p><p><strong>Body as a Whole: </strong><em>Frequent: </em>asthenia, fatigue, oedema, leg pain, malaise, sepsis, syncope. <em>Infrequent: </em>abscess, allergic reaction, allergy, chest pain precordial, choking, condition aggravated, ESR increased, flushing, hernia NOS, hot flushes, hypothermia, infection, infection fungal, infection viral, moniliasis, oedema peripheral, pallor, rigors, sudden death.</p><p>&nbsp;</p><p><strong>Cardiovascular System: </strong><em>Frequent: </em>angina pectoris, bradycardia, cardiac failure, cardiac failure left, heart murmur, oedema dependent. <em>Infrequent</em>: aneurysm, arrhythmia, cardiac arrest, embolism pulmonary, fibrillation atrial, heart block, heart disorder, hypertension aggravated, hypotension, hypotension postural, myocardial infarction, palpitation, phlebitis, pulmonary oedema, tachycardia, thrombophlebitis, thrombophlebitis deep, vascular disorder.</p><p>&nbsp;</p><p><strong>Central and Peripheral Nervous System: </strong><em>Frequent: </em>aphasia, ataxia, cerebrovascular disorder, hypokinesia, transient ischemic attack, vertigo. <em>Infrequent: </em>absences, cerebral hemorrhage, coma, convulsions, coordination abnormal, extrapyramidal disorder, hemiparesis, hemiplegia, hyperkinesia, hypertonia, hypoesthesia, muscle contractions involuntary, neuralgia, neuropathy, paralysis, paresthesia, ptosis, speech disorder, stupor, tremor.</p><p>&nbsp;</p><p><strong>Gastrointestinal System: </strong><em>Frequent: </em>abdominal pain, dyspepsia, fecal incontinence, hemorrhoids, and tooth disorder. <em>Infrequent: </em>diverticulitis, dysphagia, esophageal ulceration, esophagitis, flatulence, gastroenteritis, gastroesophageal reflux, gastrointestinal disorder NOS, GI hemorrhage, gingivitis, hemorrhage rectum, melena, mucositis NOS, oesophagitis, saliva altered, saliva increased, stomatitis ulcerative, tooth ache, tooth caries.</p><p>&nbsp;</p><p><strong>Hemic </strong><strong>and Lymphatic Disorders: </strong><em>Frequent: </em>purpura. <em>Infrequent: </em>epistaxis, hematoma, leukocytosis, leukopenia, polycythemia.</p><p>&nbsp;</p><p><strong>Metabolic and Nutritional Disorders: </strong><em>Frequent: </em>hyperglycemia, hypernatremia, hypokalemia, phosphatase alkaline increased, weight decrease. <em>Infrequent</em>: bilirubinemia, BUN increased, dehydration, diabetes mellitus, diabetes mellitus aggravated, gamma-GT increased, gout, hepatic enzymes increased, hepatic function abnormal, hypercholesterolemia, hyperkalemia, hyperuricemia, hyponatremia, NPN increased, polydipsia, AST increased, ALT increased, thirst.</p><p>&nbsp;</p><p><strong>Musculoskeletal</strong><strong> System: </strong><em>Frequent:</em><em> </em>arthritis, arthrosis, muscle weakness, myalgia. <em>Infrequent:</em></p><p>arthritis aggravated, arthritis rheumatoid, bursitis, skeletal pain.</p><p>&nbsp;</p><p><strong>Neoplasms: </strong><em>Infrequent: </em>basal cell carcinoma, breast neoplasm benign (female), breast neoplasm malignant (female), carcinoma, neoplasm NOS, skin neoplasm malignant.</p><p>&nbsp;</p><p><strong>Psychiatric Disorders: </strong><em>Frequent: </em>aggressive reaction, anorexia, apathy, cognitive disorder, delusion, nervousness. <em>Infrequent: </em>amnesia, appetite increased, concentration impaired, crying abnormal, delirium, depersonalization, emotional lability, libido increased, neurosis, paranoid reaction, paroniria, personality disorder, psychosis, sleep disorder, suicide attempt, thinking abnormal.</p><p>&nbsp;</p><p><strong>Reproductive Disorders,</strong><strong> Female: </strong><em>Infrequent: </em>vaginal hemorrhage, moniliasis;&nbsp;</p><p><strong>Male:&nbsp;</strong><em>Frequent: </em>moniliasis.</p><p>&nbsp;</p><p><strong>Respiratory</strong><strong> System: </strong><em>Frequent: </em>dyspenia, pharyngitis, pneumonia, upper respiratory tract infections, rhinitis. <em>Infrequent: </em>apnea, asthma, bronchospasm, hemoptysis, respiratory disorder, sinusitis.</p><p>&nbsp;</p><p><strong>Skin and Appendages: </strong><em>Frequent: </em>bullous eruption, herpes zoster, skin disorder, skin ulceration. <em>Infrequent: </em>alopecia, cellulitis, dermatitis, eczema, pruritus, rash erythematous, seborrhea, skin dry, skin reaction localized, urticaria.</p><p>&nbsp;</p><p><strong>Special Senses: </strong><em>Frequent: </em>cataract, conjunctivitis, eye abnormality, macula lutea degeneration, vision abnormal. <em>Infrequent: </em>blepharitis, blurred vision, conjunctival hemorrhage, corneal opacity, decreased visual acuity, diplopia, ear ache, ear disorder NOS, eye infection, eye pain, glaucoma, hearing decreased, lacrimation abnormal, myopia, xerophthalmia, retinal detachment, retinal disorder, retinal hemorrhage, tinnitus.</p><p>&nbsp;</p><p><strong>Urinary</strong><strong> System: </strong><em>Frequent: </em>cystitis, dysuria. <em>Infrequent: </em>hematuria, micturition disorder, polyuria, pyuria, renal function abnormal, urinary retention.</p><p>&nbsp;</p><p><strong>Vascular Disorders:</strong><strong> </strong><em>Infrequent: </em>venous thrombosis/ thromboembolism.</p><p>&nbsp;</p><p><strong>POST-MARKET ADVERSE DRUG REACTIONS</strong></p><p>The following adverse events of possible importance, for which there are inadequate data to determine the causal relationship to memantine treatment have been reported to be temporally associated with memantine treatment and are not described elsewhere in labeling: acne, atrioventricular block, bone fracture, carpal tunnel syndrome, cerebral infarction, cholelithiasis, claudication, colitis, depressed level of consciousness (including loss of consciousness and coma), dyskinesia, encephalopathy, gastritis, grand mal convulsions, hepatic failure, hepatitis (including increased ALT and AST), hyperlipidemia, hypoglycemia, ileus, impotence, increased INR, intracranial hemorrhage, lethargy, myoclonus, neuroleptic malignant syndrome, acute pancreatitis, aspiration pneumonia, acute renal failure, otitis media, prolonged QT interval, psychotic reactions, restlessness, sepsis, Stevens-Johnson syndrome, supraventricular tachycardia, tardive dyskinesia, thrombocytopenia.</p><p>&nbsp;</p><p>Alzheimer&rsquo;s disease has been associated with depression, suicidal ideation and suicide. In post- marketing experience these events have been reported in patients treated with memantine hydrochloride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>SYMPTOMS</strong></p><p>Cases of accidental and intentional overdose have been reported with memantine. The highest ingested dose that has been reported in an overdose is 2000 mg. Reported signs and symptoms in this case were agitation, diplopia and coma followed by full recovery. Fatal overdoses have only been reported when memantine was taken with several other drugs by patients on polytherapy that included memantine. No fatal cases of overdose have been reported in which memantine was taken alone.</p><p>&nbsp;</p><p><strong>TREATMENT OF OVERDOSAGE</strong></p><p>Because strategies for the management of overdose are continually evolving, it is advisable to contact a regional poison control center to determine the latest recommendations for the management of a suspected overdose of any drug.</p><p>Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric lavage and use of activated charcoal should be considered. Cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive measures. There are no specific antidotes for memantine hydrochloride Elimination of memantine can be enhanced by acidification of urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Persistent activation of the central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer&rsquo;s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open channel) NMDA receptor antagonist, which binds preferentially to the NMDA receptor-operated cation channels. It blocks the effects of pathologically elevated sustained levels of glutamate that may lead to neuronal dysfunction.</p><p>There is no clinical evidence that memantine prevents or slows neurodegeneration or alters the course of the underlying dementing process in patients with Alzheimer&rsquo;s disease. Memantine exhibits low to negligible affinity for other receptors (GABA, benzodiazepine, dopamine, adrenergic, noradrenergic, histamine and glycine) or voltage-dependent Ca2+, Na+&nbsp;or K+&nbsp;channels. In addition, it does not directly affect the acetylcholine receptor or cholinergic transmission, which have been implicated in the cholinomimetic side effects (e.g., increased gastric acid secretion, nausea and vomiting) seen with acetylcholinesterase inhibitors.</p><p>Memantine showed antagonist effects at the 5HT3&nbsp;receptor with potency similar to that for the NMDA receptor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ABSORPTION</strong></p><p>Orally administered memantine is completely absorbed. Oral bioavailability is almost 100%. Time to maximum plasma concentration (tmax) following single oral doses of 10 to 40 mg memantine ranged between 3 to 8 hours. It has a terminal elimination half-life of about 60-80 hours, with the majority of the dose excreted unchanged in urine. There is no indication that food influences the absorption of memantine.</p><p>Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg. Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml (0.5 - 1 &mu;<em>M</em>) with large inter-individual variations.</p><p>Approximate peak plasma memantine concentrations after single and repeated oral doses (gavage or capsule) in rat and baboon are given in the table below<strong>:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 2. Peak plasma memantine concentrations</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Species</strong></p></td><td style="vertical-align:top"><p><strong>Treatment Duration</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mg/kg)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Peak Plasma concentration (ppm)</strong></p></td></tr><tr><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Rat</p></td><td rowspan="4" style="vertical-align:top"><p>Single Dose</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>Males</p></td><td style="vertical-align:top"><p>Females</p></td></tr><tr><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>4.9</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>5-week</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>26-week</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>52-week</p></td><td style="vertical-align:top"><p>20/15 (m/f)</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>(diet)</p></td><td style="vertical-align:top"><p>40/30</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>70/50</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Baboon</p></td><td style="vertical-align:top"><p>2-week</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>13-week</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0.02</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.10</p></td><td style="vertical-align:top"><p>0.05</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>52 week</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0.01</p></td><td style="vertical-align:top"><p>0.01</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0.02</p></td><td style="vertical-align:top"><p>0.02</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.07</p></td></tr></tbody></table><p>There was no systematic sex difference, female levels were 0.5 to 2 times the male levels in various samples, with no discernible pattern (and tmax&nbsp;did not differ between the sexes).</p><p>&nbsp;</p><p><strong>DISTRIBUTION</strong></p><p>The apparent volume of distribution of memantine is approximately 9-11 L/kg and the plasma protein binding is approximately 45%. Memantine rapidly crosses the blood-brain barrier with a CSF/serum ratio of about 0.5.</p><p>Mean plasma binding of memantine in the rat is 41%, comparable to the 45% binding found in man.</p><p>Distribution studies with memantine have been carried out in rats and baboons. Oral bioavailability of memantine is virtually complete, and distribution to target, the brain, is rapid. Once in the body, memantine distributes preferentially to the organs of metabolism and excretion, liver and kidney, but also to the lung. Exceptionally high concentrations of memantine were found in bile and Harderian glands, and at lower concentrations in the central nervous system, consistent with its lipophilicity. High concentrations are also found in the uveal tract of</p><p>pigmented animals. The localization of 14C-memantine and/or its labeled metabolites in the uveal tract (which includes choroid, ciliary body and iris) of the eyes of pigmented animals (239 ppm vs. 13 ppm in albinos) suggests that the test substance has an affinity with melanin, which has also been demonstrated <em>in vitro</em>.</p><p>More pharmacologically oriented studies have focused on determining the concentration in extracellular fluid. Based on the assumption that concentrations measured in the cerebrospinal fluid (CSF) or microdialysate allow conclusions to be drawn about the concentration at the site of action, the following results are of interest. After i.p. administration of 20 mg memantine per kg to rats, about 0.3 ppm memantine was found in the microdialysate, taking the recovery into account. Under the same conditions 0.8 ppm total memantine (free and bound memantine) was found in the plasma. Similar results have been reported for humans, with a CSF/serum ratio for total memantine of about 0.4-0.6. Monitoring of the plasma concentration therefore provides information about the presumed concentration at the site of action across different species.</p><p>Following 7 days infusion of memantine (20 mg/kg/day) whole brain concentrations were 44- fold higher than free concentrations in serum. The free brain ECF concentration of memantine (0.83&plusmn;0.05 &mu;M) corrected for <em>in vivo </em>recovery (39 %) was comparable to free serum and CSF concentrations.</p><p>&nbsp;</p><p><strong>METABOLISM AND ELIMINATION</strong></p><p>In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within 20 days, more than 99% being excreted renally. Memantine undergoes little metabolism being in majority excreted unchanged in urine (75-90%). The remaining dose is converted primarily to three polar metabolites: the N-gludantan conjugate, 6-hydroxy memantine and 1- nitroso-deaminated memantine. These metabolites possess minimal NMDA receptor antagonist activity.</p><p>Memantine metabolites are mainly derivatives hydroxylated on the methyl groups (-CH2OH or &ndash;COOH) or on the cage structure, with an intact or oxidised amino function (hydroxylamino, nitro derivatives). In addition, conjugated compounds were found as phase II metabolites but they seem to be of minor importance.</p><p>The following table shows the proportion (%) of these metabolites in urine after memantine administration:</p><p><strong>Table 3. Metabolites in urine after memantine administration</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Metabolites</p></td><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>Baboon</p></td><td style="vertical-align:top"><p>Man</p></td></tr><tr><td style="vertical-align:top"><p>Unmetabolized</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>68</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxy derivatives*</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p>N-oxidized**</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Carboxy derivatives***</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>N-glucuronide****</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>6</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxylated metabolites were MRZ 2/371, 2/373, 2/374, 2/525, 2/564, 2/677</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N-oxidized (nitro, nitroso) metabolites were MRZ 2/523, 2/524, 2/529</p><p>***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MRZ 2/375</p><p>****&nbsp;&nbsp;&nbsp; MRZ 2/325.</p><p>Other metabolites found were &lt;1% in all species.</p><p>&nbsp;</p><p>Memantine and its metabolites are excreted primarily via the kidney. After a single oral dose of 14C-memantine, a minimum of 80-90% of the excreted radioactivity was excreted in the urine in rats, mice, rabbits, miniature pigs, dogs, baboons and humans.</p><p>In the baboon, a substantial portion of memantine radioactivity is associated with bile. Since excretion is predominantly renal, this indicates substantial enterohepatic circulation.</p><p>As for amantadine, memantine is partly excreted by tubular secretion.</p><p>Elimination half-life was approximately 4 hours in all species except man; there was no accumulation with repeat dosing. In baboon&rsquo;s 13 and 52 week oral toxicity studies, followed by a 4 week recovery period, no detectable memantine was present at the end of the recovery period in any tissue except the eye; concentrations in the eyes fell from 8 to 0.4 ppm during recovery in the 13 week study, and from 15 to 1 ppm in the 52 week study<strong><em>.</em></strong></p><p><strong><em>&nbsp;</em></strong>The hepatic microsome CYP450 enzyme system does not play a significant role in the metabolism of memantine<em>.</em></p><p><em>&nbsp;</em>In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m&sup2; and part of total renal clearance is achieved by tubular secretion. Renal handling also involves tubular re-absorption, probably mediated by cation transport proteins. The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 resulting in increased plasma levels of memantine (see 4.4, Genitourinary Conditions). Alkalisation of urine may result from drastic changes in diet, e.g. from a carnivore to a vegetarian diet, or from the massive ingestion of alkalising gastric buffers.</p><p>&nbsp;</p><p><strong><u>SPECIAL POPULATIONS</u></strong></p><p><strong>ELDERLY PATIENTS</strong></p><p>The pharmacokinetics of memantine in young and elderly subjects is similar. No adjustment of dosage on the basis of age is recommended.</p><p>&nbsp;</p><p><strong>REDUCED HEPATIC FUNCTION</strong></p><p>Memantine is metabolized to a minor extent into metabolites with no NMDA-antagonistic activity, and is excreted primarily in an unchanged form by the kidneys. In a study comparing the pharmacokinetics of memantine in subjects with normal hepatic function and moderate hepatic impairment (Child-Pugh B), moderate hepatic impairment did not significantly alter the pharmacokinetics of memantine following administration of a single 20 mg oral dose of memantine (see 4.4 and 4.2).</p><p>&nbsp;</p><p><strong>REDUCED RENAL FUNCTION</strong></p><p>In elderly volunteers with normal and reduced renal function (creatinine clearance of 50 to &le;80 ml/min/1.73 m&sup2;), a significant correlation was observed between creatinine clearance and total renal clearance of memantine. Following a single 20 mg oral dose of memantine, systemic exposure in geriatric subjects with mild and moderate renal impairment was 14% and 39% greater, respectively, compared to geriatric subjects with normal renal function (see 4.4 and 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ACUTE TOXICITY</strong></p><p>Acute oral and intravenous toxicity studies in rat and mouse demonstrated that memantine is moderately toxic. The lowest lethal oral dose is &ge;300 mg/kg in both species. The results of standard LD50 studies are as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Route of Administration</p></td><td style="vertical-align:top"><p>Species</p></td><td colspan="2" style="vertical-align:top"><p>LD50&nbsp;&nbsp;(mg/kg)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>Female</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Intravenous</p></td><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td style="vertical-align:top"><p>Intraperitoneal</p></td><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Subcutaneous</p></td><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>206</p></td><td style="vertical-align:top"><p>138</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>436</p></td><td style="vertical-align:top"><p>386</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Oral</p></td><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>498</p></td><td style="vertical-align:top"><p>437</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>370</p></td><td style="vertical-align:top"><p>328</p></td></tr></tbody></table><p>Toxic symptoms were similar by all administration routes: ataxia, tremor, prone position and bradypnea. These motor effects at high doses are consistent with central nervous system blockade of glutamatergic transmission in neocortex and cortical projection fields. Recovery was relatively rapid in all cases, i.e. within hours after intravenous administration and within 1-2 days after intraperitoneal, subcutaneous or oral administration. No persistent clinical signs were seen in survivors 14 days after acute high dose memantine treatment.</p><p>&nbsp;</p><p><strong><u>REPEAT-DOSE AND LONG-TERM TOXICITY</u></strong></p><p>In subchronic and chronic studies the most prominent clinical signs in all species were related to the central nervous system and included ataxia, tremor, and/or unsteadiness and aggressiveness or hyperexcitability in rodents, incoordination, tremors and apathy or quietness in dogs and baboons, and convulsions in dogs. Reduced body weight, which was sometimes accompanied by a change in food consumption, was noted in all studies.</p><p>Pathological changes, such as accumulation of foamy macrophages in several tissues, renal papillary mineralization, tubulo-interstitial nephritis, vacuolization of defined cortical neurons, and corneal opacities were observed in repeat-dose toxicity studies in rodents. The neuronal vacuolation and corneal opacities occurred at dose levels that resulted in overt toxicity.</p><p>In rats, following repeat-dose administration of memantine for various durations, the accumulation of foamy macrophages was observed in several tissues including lungs, kidneys, liver Kupffer cells, cornea, lymphoid organs, testes, epididymides and tongue muscle.</p><p>Accumulation of foamy macrophages is a form of phospholipidosis. In most tissues, except for lungs, the accumulation of foamy macrophages occurred when blood concentrations were several-fold greater than the potential concentrations in humans at therapeutic doses. In lungs, accumulations of foamy macrophages were observed when systemic exposure was less than 2- times the potential systemic exposure at human therapeutic dose levels.</p><p>Renal papillary mineralization or calcification of the collecting tubuli of the renal medulla was observed in male rats at doses of 20 mg/kg (or higher) and in female rats 15 mg/kg (or higher) following repeat-dose administration of memantine for 52-weeks or 2 years. The kidney lesions were observed at memantine blood concentrations that were less than 2-fold the potential systemic exposure in humans following repeated administration of 20 mg/day.</p><p>Cerebrocortical neurons in adult rodent brain are prone to injury (or lesions) by systemic administration of high affinity uncompetitive (or open channel) NMDA receptor antagonists, such as, (+) MK-801, PCP, and ketamine. To determine the potential of memantine to induce Olney&ndash;type lesions, studies were conducted in rats that indicated that single intraperitoneal doses of memantine of 20 mg/kg (or higher) or oral doses of 100 mg/kg (or higher) produced a dose related increase in the frequency and severity of Olney-type lesions. These experiments also indicated that vacuolization was reversible and that only a small portion of cells became necrotic. Repeated daily oral doses of 40 mg/kg/day memantine administered in a dose escalation manner did not demonstrate evidence of neurotoxicity when examined after appropriate tissue fixation procedures. Although body weight was reduced in the mid and high dose groups, no ataxia, neuronal vacuolisation or necrosis was observed at any dose level.</p><p>Experiments in rats comparing the effect of duration of dosing (acute vs. subchronic) and route of administration (dietary vs. gavage) of memantine on the development of Olney-type lesions demonstrated that regardless of duration or route of administration, ataxia occurred at doses 2 to 4 times lower than vacuolization or necrosis.</p><p>Numerous repeated dose toxicology studies with memantine were performed without any significant observations regarding neuropathology. Re-examination with appropriate preparation techniques of the existing brain tissue slides from 13-week and 52-weeks dietary study in mice and rat, respectively, and examination of the newly prepared slides from the 52- week rat study revealed no neurodegenerative changes. Histopathological examination of brains from the 13- week mouse study also revealed vacuolization in brainstem and cerebellum of males, but not cingulate and retrosplenial cortex, at 320 mg/kg/day, a dose that produced profound systemic toxicity including death.</p><p>The ability of memantine to produce Olney-type lesions in baboons was also examined. The highest dose (8 mg/kg/day) from the 52-week study was administered to baboons for 2 weeks. While ptosis was observed in all treated animals, perfusion fixation prepared brain revealed no evidence of vacuolization or necrosis. These results are consistent with the actions of other NMDA antagonists in primates, which have demonstrated that primates are resistant to the development of Olney-type lesions. Similarly in humans subjected to high doses of a low affinity uncompetitive NMDA receptor antagonist or amantadine, no necrosis in posterior cingulate/retrosplenial cortex or elsewhere in the brain was found at autopsy.</p><p>&nbsp;</p><p><strong><u>REPRODUCTION STUDIES</u></strong></p><p>Reproductive performance of rats was examined after treatment in all segments of the reproductive cycle in a series of three studies<strong><em>,</em></strong><strong><em> </em></strong>all using the same doses: 2, 6 and 18 mg/kg/day. The doses were chosen on the basis of a range-finding gavage study with low doses of up to 12.5 mg/kg, and on previous repeat dose oral studies in rats showing dose-related weight loss at 15-30 mg/kg. Treatment of female rats with memantine orally once daily during organogenesis produced mild maternal toxicity at doses of 6-18 mg/kg/day (3-9 times the Maximum Recommended Human Dose [MRHD] on a mg/m2&nbsp;basis); however, memantine was not teratogenic at doses up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis), the highest dose tested. In a rat reproduction and fertility study, reduced growth and a developmental delay were observed in offspring of mothers administered 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis).</p><p>At 30 mg/kg/day (30 times the MRHD on mg/m2&nbsp;basis) maternal toxicity and slight increase in post-implantation loss were observed in rabbits administered memantine once daily during organogenesis. No teratogenic effects were observed at that dose level. The maternal and fetal no observed effect level (NOEL) was 10 mg/kg/day (10 times the MRHD on a mg/m2&nbsp;basis).</p><p>In a peri and postnatal study, memantine was orally administered in rats at up to 18 mg/kg/day (9 times the MRHD on a mg/m2&nbsp;basis). At 18 mg/kg/day pups showed reduced mean body weights but there was no effect on their development or behaviour. Animal studies showed no indication of an adverse effect of memantine on labor and delivery.</p><p>Considering memantine&rsquo;s molecular weight and its lipophilicity, it is likely that it will be present in the treated mother&rsquo;s milk during lactation (at unknown levels). In a peri and postnatal study there were dose-related increases in memantine levels in milk in lactating rats when memantine was administered from mating through postnatal day 4, although no toxic effects were seen in suckling offspring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Component</strong></p></td><td style="vertical-align:top"><p><strong>Quality Standard</strong></p></td><td style="vertical-align:top"><p><strong>Function</strong></p></td><td style="vertical-align:top"><p><strong>%w/w</strong></p></td><td style="vertical-align:top"><p><strong>mg/tab</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Core</strong></p></td></tr><tr><td style="vertical-align:top"><p>Memantine Hydrochloride</p></td><td style="vertical-align:top"><p>IH</p></td><td style="vertical-align:top"><p>Active</p></td><td style="vertical-align:top"><p>4.22</p></td><td style="vertical-align:top"><p>10.00</p></td></tr><tr><td style="vertical-align:top"><p>Lactose Monohydrate (Supertab 11SO)</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Diluent</p></td><td style="vertical-align:top"><p>67.51</p></td><td style="vertical-align:top"><p>160.0</p></td></tr><tr><td style="vertical-align:top"><p>Microcrystalline Cellulose &nbsp;(PH102)</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Diluent</p></td><td style="vertical-align:top"><p>24.05</p></td><td style="vertical-align:top"><p>57.0</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose Sodium</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Disintegrant</p></td><td style="vertical-align:top"><p>0.42</p></td><td style="vertical-align:top"><p>1.00</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Lubricant</p></td><td style="vertical-align:top"><p>0.84</p></td><td style="vertical-align:top"><p>2.00</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Total</strong></p></td><td style="vertical-align:top"><p><strong>97.05</strong></p></td><td style="vertical-align:top"><p><strong>230</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Film Coated Tablets</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methylcellulose 2910 E5</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Film Forming Polymer</p></td><td style="vertical-align:top"><p>1.25</p></td><td style="vertical-align:top"><p>2.96</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Cellulose Type LF</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Film Forming Polymer</p></td><td style="vertical-align:top"><p>0.42</p></td><td style="vertical-align:top"><p>0.986</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene Glycol 8000</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Plasticizer</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>1.971</p></td></tr><tr><td style="vertical-align:top"><p>Titanium Dioxide</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Opacifying Agent</p></td><td style="vertical-align:top"><p>0.42</p></td><td style="vertical-align:top"><p>0.986</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water*</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Solvent</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>91.7</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Total</strong><strong> </strong><strong>coating</strong><strong> </strong><strong>solution (excluding purified water)</strong></p></td><td style="vertical-align:top"><p><strong>2.91</strong></p></td><td style="vertical-align:top"><p><strong>6.90</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Total</strong><strong> </strong><strong>Coated Tablet Weight</strong></p></td><td style="vertical-align:top"><p><strong>100</strong></p></td><td style="vertical-align:top"><p><strong>237</strong></p></td></tr></tbody></table><p>IH: In-house</p><p>*Purified water, used in the coating solution, is removed during coating process.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Unit Count or Fill &nbsp;Size</p></td><td style="vertical-align:top"><p>Strength</p></td><td style="vertical-align:top"><p>Description</p></td></tr><tr><td style="vertical-align:top"><p>30&#39;s</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>Film PVC/PVdC Clear 10MIL 250/60 205MM Silver plain foil 205MM 25UM</p></td></tr></tbody></table><p>Secondary Packaging: Carton</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APOTEX INC.
150 Signet Drive Toronto, Toronto, Ontario
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>